[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351920-105":59,"doc-detail-351920-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","efficacy-and-safety-of-nanoliposomal-irinotecan-plus-5-fluorouracil-and-l-leucovorin-in-rare-histological-subtypes-of-pancreatic-cancer","Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer","","Pancreatic cancers other than pancreatic ductal adenocarcinoma (PDAC) are rare and heterogeneous, representing fewer than 5%–7% of cases. Optimal treatment sequencing, especially beyond first line, remains unclear for these subtypes. This retrospective study evaluated nine patients with rare histological pancreatic cancer subtypes receiving nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV) between June 2020 and November 2024. Partial responses occurred in four patients, disease control in 77.8%, median progression-free survival 6.8 months, and toxicity was generally manageable with neutropenia most common (grade ≥3).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-nanoliposomal-irinotecan-plus-5-fluorouracil-and-l-leucovorin-in-rare-histological-subtypes-of-pancreatic-cancer/351920/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-nanoliposomal-irinotecan-plus-5-fluorouracil-and-l-leucovorin-in-rare-histological-subtypes-of-pancreatic-cancer/351920.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which patient population was evaluated in this study?","Question",{"text":113,"@type":114},"Nine patients with rare histological subtypes of pancreatic cancer that were unresectable at diagnosis and had shown disease progression during prior systemic therapy were evaluated.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What regimen did the study investigate?",{"text":118,"@type":114},"The study investigated nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV).",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main efficacy outcomes and safety observations?",{"text":122,"@type":114},"Partial responses were observed in four patients and disease control was achieved in seven patients (77.8%), with median progression-free survival of 6.8 months. Treatment-related toxicities were generally manageable, and neutropenia was the most common grade ≥3 adverse event.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},351920,1790114019,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Japanese Journal of Clinical Oncology, 2026, 56(7), 858–864 [https://doi.org/10.1093/jjco/hyag044](https://doi.org/10.1093/jjco/hyag044)  \n[Published: 20 March 2026](Published: 20 March 2026)  \nOriginal Article  \n| Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer\u003Cbr>Tomonao Taira , Tomoyuki Satake* , Go Igarashi, Kanae Inoue, Taro Shibuki, Masataka Amisaki, Mitsuhito Sasaki, Hideaki Takahashi, Hiroshi Imaoka , Shuichi Mitsunaga, Masafumi Ikeda  |  |\n| --- | --- |\n| Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan\u003Cbr>*Corresponding author. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. E-mail: [tosatake@east.ncc.go.jp](tosatake@east.ncc.go.jp).\u003Cbr>Abstract\u003Cbr>Background: Pancreatic cancers other than pancreatic ductaladenocarcinoma (PDAC) are rare and heterogeneous, accounting for fewer than 5%–7% of all pancreatic cancers. These include acinar cell carcinoma, undifferentiated carcinoma, adenosquamous carcinoma, colloid carcinoma, neuroendocrine carcinoma (NEC), mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), and invasive intraductal papillary mucinous carcinoma (IPMC). Optimal treatment strategies, including sequencing and later-line options, remain unclear. Although nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV) is effective in gemcitabine-refractory PDAC, its role in these rare subtypes is unknown.\u003Cbr>Methods: We retrospectively analyzed nine patients with one of these rare subtypes who received nal-IRI plus 5-FU and LV between June 2020 and November 2024. Efficacy and safety were evaluated.\u003Cbr>Results: The cohort included two cases each of IPMC and adenosquamous carcinoma, and one case each of colloid carcinoma, undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN. Partial responses were observed in four patients, including undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN, even among tumors refractory to gemcitabineor platinum-based regimens. Disease control was achieved in seven patients (77.8%). The median progression-free survival was 6.8 months. Disease control exceeding 12 months was observed in three patients. Median overall survival from first-line therapy was not reached. Treatment-related toxicities were generally manageable, with neutropenia being the most common grade ≥ 3 adverse event.\u003Cbr>Conclusion: Nal-IRI plus 5-FU and LV showed antitumor activity and was tolerable among the nine patients analyzed in this study, suggesting it may be a therapeutic option in second-or later-line settings for rare pancreatic cancer.\u003Cbr>Keywords pancreatic cancer, second-line therapy, systemic chemotherapy, treatment outcome |  |\n| Introduction\u003Cbr>Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignancies and is characterized by a highly aggressive clinical course and poor prognosis [1, 2] . For patients with unresectable PDAC, standard first-line treatment agents include nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV) plus oxaliplatin (NALIRIFOX) or folinic acid, LV, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel (GnP) [3–5] . Based on the results reported from the NAPOLI-1 trial, nal-IRI plus 5-FU and LV became established as an effective regimen in the second-line setting for patients showing disease progression after gemcitabine-based chemotherapy [6, 7] . | In contrast, pancreatic cancers other than conventional PDAC, including acinar cell carcinoma, undifferentiated carcinoma, adenosquamous carcinoma, colloid carcinoma, neuroendocrine carcinoma (NEC), mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), and invasive intraductal papillary mucinous carcinoma ","cbCaidaKQQJZzHea","https://ap.wps.com/l/cbCaidaKQQJZzHea","pdf",573908,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Which patient population was evaluated in this study?\",\"answer\":\"Nine patients with rare histological subtypes of pancreatic cancer that were unresectable at diagnosis and had shown disease progression during prior systemic therapy were evaluated.\"},{\"question\":\"What regimen did the study investigate?\",\"answer\":\"The study investigated nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV).\"},{\"question\":\"What were the main efficacy outcomes and safety observations?\",\"answer\":\"Partial responses were observed in four patients and disease control was achieved in seven patients (77.8%), with median progression-free survival of 6.8 months. Treatment-related toxicities were generally manageable, and neutropenia was the most common grade ≥3 adverse event.\"}]","Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer | PDF",1790096503,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36a5513888f72afbe28fdefbd68d862f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9da01890b3bda5fd3fe7b62146107406.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f96ef8a4ac6f4f5a57ee4b13290f25df.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2e9400b91cba64fec8564ee2657cc58.webp",980,1287]